Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Turkey / NCT06753812
Enrolling by invitation Not applicable

Investigation of the Effect of Constraint Induced Movement Therapy Applied to the Lower Extremity on Lower Extremity Functions in Individuals With Unilateral Cerebral Palsy

NCT06753812 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2025-01-15
Last updated
2024-12-31

Condition(s) studied

Cerebral Palsy Spastic Hemiplegic

Investigational drug(s) / intervention(s)

constraint induced movement therapyControl (Standard treatment)

constraint induced movement therapy: Children in this group will receive constraint induced movement therapy for 10 sessions over 2 weeks, each session lasting 90 minutes, in addition to the treatment they receive 2 days a week at the special education and rehabilitation centers they attend.

Control (Standard treatment): Children in this group will continue to receive their treatment at the special education and rehabilitation center they attend, two days a week for 40 minutes.

Study summary

Lower extremity constraint induced movement therapy has been applied to individuals with multiple sclerosis, stroke, subacute and chronic hemiparesis in recent years and positive results have been reported. However, there is no study in the literature regarding the application of this treatment method to the pediatric population. In order to address this gap in the literature, we planned to conduct this study to examine the possible effects of lower extremity constraint induced movement therapy on lower extremity functions, balance and gait parameters in individuals with cerebral palsy.

Eligibility

Sex
ALL
Min age
5 Years
Max age
15 Years
Healthy volunteers
No
Inclusion Criteria: * Having been diagnosed with Cerebral Palsy by a Child Neurologist. * Having been classified as Unilateral Cerebral Palsy according to SCPE. * Being between the ages of 5-15, * Being at levels I-II according to the Gross Motor Function Classification System * Being at levels I-II according to the Communication Function Classification System * Being able to stand up from sitting independently, even with the help of the upper extremity * Being able to walk at least 10 m with or without an assistive device Exclusion Criteria: * Children who have had lower extremity orthopedic surgery within the last six months * Children who have had lower extremity Botox injections within the last six months * Those with rigid contractures involving lower extremity joints, * Children with levels III-IV according to the Communication Functions Classification System * Families and children who do not accept full participation in treatment

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Bolu Abant İzzet Baysal University Faculty of Health Sciences Bolu Turkey (Türkiye)

More Abant Izzet Baysal University trials in Turkey

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06753812 on ClinicalTrials.gov ↗ ← All trials in Turkey